BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
$10.98
arrow_downward
-1.04%(-0.12) 1D
Oct 7, 9:43:10 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
$10.96
High
$10.98
Low
$10.96
Mkt. cap
2.56B
Avg. vol.
2.49K
Volume
400.00
P/E ratio
11.73
52-wk high
$13.00
52-wk low
$8.67
EPS
$0.94
Beta
1.45
Shares outstanding
237.82M
No. of employees
2K
Open
$10.96
High
$10.98
Low
$10.96
Mkt. cap
2.56B
Avg. vol.
2.49K
Volume
400.00
P/E ratio
11.73
52-wk high
$13.00
52-wk low
$8.67
EPS
$0.94
Beta
1.45
Shares outstanding
237.82M
No. of employees
2K
News stories
From web sources and news partners
TradingView
·
32 minutes ago
S&P 500 stocks with negative beta hit record 130
Economies.com
·
1 hour ago
Nasdaq and S&P 500 retreat from record highs as yields and oil prices rise
ChartMill
·
1 hour ago
Wednesday's session: gap up and gap down stock in the S&P500 index
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com